UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. | Other Events. |
IO Biotech, Inc. (the “Company”) expects to hold the Company’s first annual meeting of stockholders (the “2022 Annual Meeting”) on Wednesday, May 25, 2022. A proxy statement with further information regarding the 2022 Annual Meeting will be distributed to stockholders prior to such meeting.
Deadline for Rule 14a-8 Stockholder Proposals
Under the Securities and Exchange Commission’s proxy rules, the Company has set the deadline for submission of proposals to be included in the proxy materials for the 2022 Annual Meeting as March 26, 2022. Accordingly, in order for a stockholder proposal to be considered for inclusion in the Company’s proxy materials for the 2022 Annual Meeting, the proposal must be received by the Company at IO Biotech ApS, Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark, Attention: Corporate Secretary, on or before March 26, 2022, and comply with the procedures and requirements set forth in Rule 14a-8 under the Securities Exchange Act of 1934.
Advance Notice Deadline for Director Nominations and Other Stockholder Proposals
In accordance with the Company’s Bylaws, for director nominations or stockholder proposals to be brought before the 2022 Annual Meeting, other than Rule 14a-8 proposals described above, written notice must be received by the Company at IO Biotech ApS, Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark, Attention: Corporate Secretary, by March 26, 2022. Such notices must also comply with the requirements of the Company’s Bylaws and other applicable law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IO BIOTECH, INC. | ||||||
Date: March 16, 2022 | By: | /s/ Mai-Britt Zocca | ||||
Name: | Mai-Britt Zocca, Ph.D. | |||||
Title: | Chief Executive Officer |
Document and Entity Information |
Mar. 16, 2022 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001865494 |
Document Type | 8-K |
Document Period End Date | Mar. 16, 2022 |
Entity Registrant Name | IO BIOTECH, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-41008 |
Entity Tax Identification Number | 87-0909276 |
Entity Address, Address Line One | Ole Maaløes Vej 3 |
Entity Address, Postal Zip Code | DK-2200 |
Entity Address, City or Town | Copenhagen N |
Entity Address, Country | DK |
City Area Code | +45 |
Local Phone Number | 7070 2980 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | IOBT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
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end
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